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The role of molecular analysis in the management of gastrointestinal stromal tumors (GIST) remains indisputable.
To date, tumor tissue extracted from specimens obtained by surgical or biopsy procedures has been the only
source of the tumor DNA required for the molecular and genomic assessment of cancer. However, tumor tissue
sampling has several clinical limitations: for example, the invasiveness of these procedures precludes repeated
sampling. Thus, it is possible to obtain only a static molecular picture of the disease, a picture that lacks the
inter- and intra-metastatic molecular heterogeneity that characterizes most GIST. In contrast, circulating tumor
DNA obtained from a patient’s bloodstream, known as liquid biopsy, can theoretically overcome the limitations of
tissue biopsies and provide the same molecular and genomic information. GIST are recognized as a paradigm of
molecular biology among solid tumors. Although few but promising data on liquid biopsy in GIST have been
accumulated to date, these tumors may provide the optimal field for application of this challenging approach.
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The role of molecular analysis in the management of
gastrointestinal stromal tumors (GIST) remains unex-
plored [1,2]. Knowledge of mutational status provides cli-
nicians with a mandatory guide to therapeutic decision
making concerning GIST patients with advanced disease
[3-5]. Mutational analysis has also been advocated in the
adjuvant setting [6-8]: a recent trial on the relationship be-
tween tumor genotype and benefits of adjuvant imatinib
reported that GIST with a KIT exon 11-deletion respond
positively to treatment, with a significantly longer
recurrence-free survival compared with placebo. However,
this benefit was not observed for GIST KIT exon 11 point
mutations and insertions, or KIT exon 9 or KIT/platelet-
derived growth factor receptor alpha (PDGFRA) wild type
(WT) [2].
To date, tumor tissue extracted from specimens obtained
by surgical or biopsy procedures has been the only source
of the tumor DNA required for the molecular and genomic
assessment of cancer. However, such tumor tissue* Correspondence: maria.pantaleo@unibo.it
1Department of Specialized, Experimental and Diagnostic Medicine,
Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna 40138, Italy
2“Giorgio Prodi” Cancer Research Center, University of Bologna, Bologna
40138, Italy
© 2014 Nannini et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.sampling has several clinical limitations: because it is
obtained by invasive procedures that can have complica-
tions, it cannot be repeated frequently. In the absence of
serial samples for analysis, only a static molecular picture
of the disease, a picture that lacks the inter- and intra-
metastatic molecular heterogeneity characteristic of most
GISTs, is available [9,10]. Moreover, tumor tissue in
formalin-fixed paraffin-embedded blocks is not optimal for
wide genome analysis, which requires high-throughput
technologies for which fresh DNA is more suitable.
In the scenario under review here, circulating tumor
DNA (ctDNA) obtained from a patient’s bloodstream,
known as liquid biopsy, can theoretically overcome all
the limitations of tissue biopsies and provide the same
molecular and genomic information [11]. Because blood
sampling is minimally invasive, it can be performed at
any time during the course of the disease, allowing dy-
namic assessment of molecular changes in tumors over
time. Moreover, it can provide the fresh tumor DNA
needed for whole genome and exome analyses.
ctDNA investigations in cancer patients are increasingly
being performed, supporting the different potential applica-
tions of this approach. Preliminary studies in patients with
melanoma, ovarian, breast, prostate, and colon cancers havel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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burden, suggesting a potential role for ctDNA as a surrogate
marker of tumor response to treatment [12-16]. Addition-
ally, detection of ctDNA after radical surgery or curative
therapies indicates the presence of minimal residual disease
and may thus identify patients who will experience tumor
recurrence [12]. Other studies have shown that serial ana-
lysis of ctDNA during treatment can provide a dynamic pic-
ture of molecular disease changes, suggesting that this
noninvasive approach could also be used to monitor the de-
velopment of secondary resistance and identify heteroge-
neous subclonal populations of tumor cells developing
during the course of treatment [17]. Such a monitoring ap-
plication should be extremely useful during treatment of
cancer with tyrosine-kinase inhibitors (TKIs). Finally, differ-
ent strategies for detecting novel chromosomal alterations
in plasma, such as rearrangements and amplification or epi-
genetic changes, have recently been developed, suggesting
that ctDNA could also be used for detecting new tumor-
derived variants for genotyping purposes [18-20].
Review
Because the application of liquid biopsy in GIST has only
been reported in the last year, few but promising data are
now available [21,22]. The feasibility of liquid biopsy and
its application in GISTs was reported for the first time at
the 2013 ASCO Annual Meeting [21,22]. Using both
Sanger sequencing on tumor tissue and Beads Emulsion
Amplification Magnetics technology on plasma, Demetri
et al. have analyzed the kinase genotypes in a subgroup of
GIST patients in a phase III GRID trial [21]. They found
84% concordance between plasma and tissue for detection
of primary KIT mutations. Additionally, they more easily
detected secondary mutations in plasma (47%) than in tis-
sue (12%). In contrast, the assay was less sensitive for the
detection of primary KIT exon 11 mutations in plasma
DNA (12% vs 43%), this apparent discrepancy being partly
attributable to the study design, which was specifically tar-
geted to secondary mutations, but mostly to the extensive
heterogeneity of primary KIT exon 11 mutations that
hampers the development of specific assays for each pos-
sible mutation carried by the tumor. These findings high-
light a possible limitation of liquid biopsy that is shared by
all other technologies specifically designed to identify
KIT/PDGFRA mutations in GIST management; namely,
the wide variability of tyrosine kinase mutations. Thus,
less targeted approaches may be better able to provide a
complete sequence of the hotspot exons such as CAPP-
Seq or TAm-Seq. However, even in this scenario the very
large insertions and deletions barely detected by massively
parallel sequencing would constitute a drawback [23,24].
Maier et al. retrospectively used 25 different allele-specific
L-polymerase chain reaction assays covering KIT and
PDGFRA mutations to examine 291 plasma samples from38 GIST patients and correlated the detection of mutated
ctDNA with disease status (active disease vs complete re-
sponse [CR]) [22]. Interestingly, they found that, in the
clinical setting, more patients with active disease, defined
as patients having at least one lesion progressing or
responding to treatment, had positive results than did CR
patients without evidence of residual disease after surgery.
They also examined whether the amount of ctDNA corre-
lated with tumor radiological response and reported re-
peated positive test results and increasing mutant ctDNA
in patients with disease progression, negative to positive
conversions in patients with relapse, and positive to nega-
tive conversions in patients responding to TKIs. Taken to-
gether, these findings indicate that mutant ctDNA can be
detected and quantified in the plasma of GIST patients
and, notably, that the amount of mutant ctDNA correlates
with tumor response, suggesting that this approach is feas-
ible and can be used as a surrogate biomarker for predict-
ing both tumor response and relapse in GIST patients.
Although very few data have been accumulated to date,
liquid biopsy seems to be a promising tool in GIST man-
agement, offering a wide spectrum of clinical applications.
The well-known kinase genotype and its relationship with
tumor response to TKIs has made GIST a paradigm of
molecular biology among solid tumors and provides a
strong rationale for applying liquid biopsy in this disease.
In particular, the possibility of taking serial blood samples
to assess real-time molecular modifications during the
course of treatment may identify the development of het-
erogeneous resistant clones, thereby optimizing the timing
of changes in therapeutic strategy. However, because the
therapeutic armamentarium available for advanced GIST
is limited, this noninvasive approach should not be applied
only to anticipate changes in treatment, but also to guide
clinicians in re-challenging with drugs according to a rota-
tion strategy.
In addition to offering a dynamic picture of molecular
changes during the course of a disease that could serve as
early biomarkers of tumor response to TKIs, other intri-
guing applications of liquid biopsy in GIST management
are possible. First, it could be used to assess minimal re-
sidual disease after radical resection of a primary tumor,
thus accurately identifying patients at high risk of recur-
rence for whom adjuvant treatment is indicated. Plainly,
the main limitation of this application is the ability of the
methods used to detect very small amounts of ctDNA;
more sensitive assays should be developed for this pur-
pose. Moreover, in the light of the extreme biological het-
erogeneity of GIST, especially those without the known
KIT/PDGFRA or BRAF/RAS/NF1 or SDH mutations
(termed WT GIST), liquid biopsy may be the best tool for
obtaining a wide molecular picture of GIST by using
whole genome analyses with high-throughput technolo-
gies, such as next-generation sequencing approaches.
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chromosomal adaptations such as rearrangements and
translocations, thus overcoming the limitations of creating
fresh tissue banks. This would facilitate a more detailed
molecular classification of this disease and shed light on
new diagnostic and prognostic biomarkers and eventually
new potential targets, thereby extending the therapeutic
armamentarium for a subset of GIST. Finally, liquid bi-
opsy could also be used to select patients for clinical trials
according to their molecular profile, rather than relying
solely on the standard clinical and pathological features
adopted to date.
Conclusions
Liquid biopsy is emerging as one of the most challenging
and promising tools in oncology. Because GIST are rec-
ognized as the paradigm of molecular biology in solid
tumors, these tumors represent an optimal field in which
to use this approach.
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